The plasminogen activation system in tumour invasion and metastasis

被引:41
作者
deVries, TJ
vanMuijen, GNP
Ruiter, DJ
机构
[1] Department of Pathology, University Hospital, Nijmegen
[2] Dept. of Pathology, University Hospital, NL-6500 HB Nijmegen
关键词
urokinase; plasminogen activator; histochemistry; prognostic factor;
D O I
10.1016/S0344-0338(96)80094-X
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The involvement of proteases in the metastatic spread of tumour cells and in tumour related processes, such as angiogenesis and ulceration, has been known for many decades. This chapter reviews the involvement of one proteolytic system - the plasminogen activation system - in tumour progression. In recent years, many biochemical properties of the various components of the plasminogen activation system have become known. These properties and the functional relationship between the components are discussed in the first section. Since interfering with proteolysis by tumour cells and by newly formed endothelial cells can be an objective for future therapy, experimental tumour models have been used to study the effects of inhibitors of plasminogen activation. The second section deals with this issue. Finally, the presence of the various components of the plasminogen activation system in human tumours is reviewed. Following the availability of specific ELISAs, antibodies and molecular probes, the content and the cellular distribution of the components of the plasminogen activation system have recently been mapped in various human tumours.
引用
收藏
页码:718 / 733
页数:16
相关论文
共 246 条
[111]   STRUCTURES AND FUNCTIONS OF MULTILIGAND LIPOPROTEIN RECEPTORS - MACROPHAGE SCAVENGER RECEPTORS AND LDL RECEPTOR-RELATED PROTEIN (LRP) [J].
KRIEGER, M ;
HERZ, J .
ANNUAL REVIEW OF BIOCHEMISTRY, 1994, 63 :601-637
[112]   PLASMINOGEN-ACTIVATOR INHIBITORS - A REVIEW [J].
KRUITHOF, EKO .
ENZYME, 1988, 40 (2-3) :113-121
[113]   TISSUE PLASMINOGEN-ACTIVATOR AND INHIBITORS OF FIBRINOLYSIS IN MALIGNANT-MELANOMA [J].
KWAAN, HC ;
RADOSEVICH, JA ;
XU, CG ;
LASTRE, C .
TUMOR BIOLOGY, 1988, 9 (06) :301-&
[114]  
LANDAU BJ, 1994, CANCER RES, V54, P1105
[115]  
LARSSON G, 1987, THROMB HAEMOSTASIS, V58, P822
[116]  
LAUG WE, 1993, CANCER RES, V53, P6051
[117]   OCCURRENCE OF THE SPECIFIC PLASMINOGEN-ACTIVATOR INHIBITOR OF PLACENTAL TYPE, PAI-2 IN ASCITIC FLUID AND TUMOR VESSEL BLOOD FROM PATIENTS WITH OVARIAN-CARCINOMA [J].
LECANDER, I ;
MARTINSSON, G ;
CASSLEN, B ;
ANDREASEN, PA ;
ASTEDT, B .
FIBRINOLYSIS, 1990, 4 (04) :221-224
[118]  
LENGYEL E, 1995, CANCER RES, V55, P963
[119]  
LIOTTA LA, 1991, CANCER RES, V51, pS5054
[120]   COEXPRESSION OF UROKINASE, UROKINASE RECEPTOR AND PAI-1 IS NECESSARY FOR OPTIMUM INVASIVENESS OF CULTURED LUNG-CANCER CELLS [J].
LIU, GH ;
SHUMAN, MA ;
COHEN, RL .
INTERNATIONAL JOURNAL OF CANCER, 1995, 60 (04) :501-506